Neoadjuvant HER2+ Articles | Page 3

Blackwell Sheds Light on Recent Advances in HER2+ Breast Cancer
Kimberly L. Blackwell, MD, discusses novel agents and other recent advancements in the treatment paradigm of HER2-positive breast cancer.
Neoadjuvant Palbociclib/Pertuzumab Regimen Active in ER/HER2-Positive Breast Cancer
The neoadjuvant combination of palbociclib (Ibrance), pertuzumab (Perjeta), fulvestrant (Faslodex), and trastuzumab (Herceptin), cut expression of Ki67 and induced an overall clinical response of 29% in women with ER-positive/HER2-positive breast cancer.
Tucatinib Combo Explored in HER2-Positive Breast Cancer
Rashmi K. Murthy, MD, MBE, discusses the role of tucatinib in CNS metastases for patients with HER2-positive breast cancer.
Trastuzumab Biosimilar Demonstrates Equivalence in HER2+ Breast Cancer
The trastuzumab (Herceptin) biosimilar SB3 induced a rate of breast pathologic complete response similar to trastuzumab in women with HER2-positive breast cancer, according to results from a phase III study of 800 patients.
Study Finds No Cardiac Toxicity Increase With Trastuzumab in HER2+ Breast Cancer Patients
Trastuzumab did not reduce cardiac function in women with node-positive, HER2+, early-stage breast cancer.
Novel Treatments Emerging in HER2+ Breast Cancer Pipeline
Aleix Prat, MD, PhD, discusses the novel treatments being developed in the paradigm of HER2-positive breast cancer.
Pertuzumab and Other Agents Continue Progress in HER2+ Breast Cancer
Adam M. Brufsky, MD, PhD, discusses the developing role of pertuzumab in HER2-positive breast cancer, as well as the impact of other agents in the field.
Dual HER2 Blockade Superior for PFS in HER2+/HR+ Metastatic Breast Cancer
The combination of lapatinib, trastuzumab, and an aromatase inhibitor (AI) reduced the risk for death or progression by 38% in women with HER2+/HR+ metastatic breast cancer compared with those treated with a targeted agent plus AI.
Long-Term Data Published for Neratinib in HER2+ Breast Cancer
Extended adjuvant therapy with neratinib significantly reduced the proportion of clinically relevant breast cancer relapses without increasing the risk of long-term toxicity.
Hamilton Highlights Treatment Landscape of HER2+ Breast Cancer
Erika P. Hamilton, MD, discusses recent FDA approvals in the treatment paradigm of HER2-positive breast cancer.
Publication Bottom Border
Border Publication